RxDoctor Payments DataLook up a doctor →

Heather Oconnell, PA

Medical · Peoria, AZNPI 1730550799

Payments from drug & device makers

$29,760in general payments, 2019–2025

Across 761 payments — averaging $39.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$12K
  • AstraZeneca$3K
  • Phadia US Inc.$2K
  • GSK$1K
  • Optinose US, Inc.$1K
  • Sanofi$1K
  • plus $9K from 35 others

What the payments were for

  • Consulting fees$7,88426%
  • Speaking & faculty fees$2,5509%
  • Travel & lodging$1,9727%
  • Food & beverage$17,31158%
  • Education$430%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,760 in reported general payments places this provider in the 95th percentile of 748 medical providers in Arizona.

See all medical providers in Arizona

Medicare billing

Part B allowed, 2024
$123,783
Medicare patients
44
Services billed
4,612

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
HaegardaC1 Esterase Inhibitor13$461,568
Dupixent SyringeDupilumab39$165,877
HyqviaIgg/Hyaluronidase,recombinant15$120,276
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$26,136
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$16,946
Spiriva RespimatTiotropium Bromide18$13,908
Breo ElliptaFluticasone/Vilanterol15$8,566
SymbicortBudesonide/Formoterol Fumarate16$6,295
Epinephrine22$4,603
Azelastine Hcl78$3,689
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,514
Ipratropium Bromide38$1,244
Albuterol Sulfate HfaAlbuterol Sulfate38$1,040
Montelukast Sodium57$426
Fluticasone Propionate22$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHaegarda$703$461,56813 claims
Takeda Pharmaceuticals U.S.A., Inc.Hyqvia$942$120,27615 claims
GSKTrelegy Ellipta, Breo Ellipta$1,365$34,70250 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,752$23,24138 claims
Boehringer IngelheimSpiriva Respimat$152$13,90818 claims
Hikma Pharmaceuticals USAEpinephrine$17$4,60322 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 748 medical providers in Arizona.

Other medical in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →